Teriparatide in the management of osteoporosis

Donald Bodenner, Carolyn Redman, Ann RiggsDepartment of Geriatrics, University of Arkansas for Medical Sciences, Little Rock, AR, USAAbstract: Fracture of the hip is frequently a catastrophic event in the elderly, often resulting in death within a year and of the survivors, few regain pre-fracture q...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Donald Bodenner, Carolyn Redman, Ann Riggs
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/a5cf8e1f0d1a4fe8a403920060f913d4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a5cf8e1f0d1a4fe8a403920060f913d4
record_format	dspace
spelling	oai:doaj.org-article:a5cf8e1f0d1a4fe8a403920060f913d42021-12-02T04:41:36ZTeriparatide in the management of osteoporosis1178-1998https://doaj.org/article/a5cf8e1f0d1a4fe8a403920060f913d42008-01-01T00:00:00Zhttps://www.dovepress.com/teriparatide-in-the-management-of-osteoporosis-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Donald Bodenner, Carolyn Redman, Ann RiggsDepartment of Geriatrics, University of Arkansas for Medical Sciences, Little Rock, AR, USAAbstract: Fracture of the hip is frequently a catastrophic event in the elderly, often resulting in death within a year and of the survivors, few regain pre-fracture quality of life. Although less appreciated, fractures of the spine result in significant morbidity and are also associated with increased mortality compared with individuals without a fracture. In recent years there has been an explosion in the development of new drugs for the treatment of osteoporosis. Recombinant human parathyroid hormone (1–34) (20 μg/day) is a recent addition to this armamentarium with a novel mechanism of action, which was approved by the US FDA for the treatment of postmenopausal osteoporosis and male osteoporosis secondary to hypogonadism in November 2002. It is the first osteoporosis treatment that leads to the formation of new bone with architecture similar to normal bone. Intense efforts have been made to understand the effect of teriparatide on antiresorptive therapy and vice versa. Although these relationships are not completely understood, the results of recent studies allow clinicians to begin to optimize therapeutic gains in bone mineral density and improve anti-fracture efficacy.Keywords: osteoporosis, teriparatide, fractureDonald BodennerCarolyn RedmanAnn RiggsDove Medical PressarticleGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 2, Pp 499-507 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	Geriatrics RC952-954.6
spellingShingle	Geriatrics RC952-954.6 Donald Bodenner Carolyn Redman Ann Riggs Teriparatide in the management of osteoporosis
description	Donald Bodenner, Carolyn Redman, Ann RiggsDepartment of Geriatrics, University of Arkansas for Medical Sciences, Little Rock, AR, USAAbstract: Fracture of the hip is frequently a catastrophic event in the elderly, often resulting in death within a year and of the survivors, few regain pre-fracture quality of life. Although less appreciated, fractures of the spine result in significant morbidity and are also associated with increased mortality compared with individuals without a fracture. In recent years there has been an explosion in the development of new drugs for the treatment of osteoporosis. Recombinant human parathyroid hormone (1–34) (20 μg/day) is a recent addition to this armamentarium with a novel mechanism of action, which was approved by the US FDA for the treatment of postmenopausal osteoporosis and male osteoporosis secondary to hypogonadism in November 2002. It is the first osteoporosis treatment that leads to the formation of new bone with architecture similar to normal bone. Intense efforts have been made to understand the effect of teriparatide on antiresorptive therapy and vice versa. Although these relationships are not completely understood, the results of recent studies allow clinicians to begin to optimize therapeutic gains in bone mineral density and improve anti-fracture efficacy.Keywords: osteoporosis, teriparatide, fracture
format	article
author	Donald Bodenner Carolyn Redman Ann Riggs
author_facet	Donald Bodenner Carolyn Redman Ann Riggs
author_sort	Donald Bodenner
title	Teriparatide in the management of osteoporosis
title_short	Teriparatide in the management of osteoporosis
title_full	Teriparatide in the management of osteoporosis
title_fullStr	Teriparatide in the management of osteoporosis
title_full_unstemmed	Teriparatide in the management of osteoporosis
title_sort	teriparatide in the management of osteoporosis
publisher	Dove Medical Press
publishDate	2008
url	https://doaj.org/article/a5cf8e1f0d1a4fe8a403920060f913d4
work_keys_str_mv	AT donaldbodenner teriparatideinthemanagementofosteoporosis AT carolynredman teriparatideinthemanagementofosteoporosis AT annriggs teriparatideinthemanagementofosteoporosis
_version_	1718401141746696192

Teriparatide in the management of osteoporosis

Ejemplares similares